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Mario Lima5 and Andrea Pession1Abstract
The syndrome of immune dysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) is a rare disorder caused
by mutations in the FOXP3 gene. Diarrhea, diabetes and dermatitis are the hallmark of the disease, with a typical
onset within the first months of life. We describe the case of a twelve-year old male affected by a very late-onset
IPEX with intractable enteropathy, which markedly improved after starting Sirolimus as second-line treatment. This
case suggests that IPEX should always be considered in the differential diagnosis of watery intractable diarrhea,
despite its unusual onset.
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box P3 (FOXP3)Correspondence
The syndrome of immune dysregulation, polyendocrino-
pathy, enteropathy, X-linked (IPEX) is a rare disorder,
characterized by diarrhea, type-1 diabetes mellitus (T1DM)
and dermatitis with onset within the first months of life
[1,2]. Diarrhea is intractable and persists despite dietary
exclusions and bowel rest, resulting in malabsorption and
failure to thrive [3]; T1DM can precede or follow enteritis
[4-6]; dermatitis is severe with eczematiform, ichthyosi-
form or psoriasiform aspects [7-10], other autoimmune
diseases are often associated [11].
IPEX is caused by germ-line mutations in the FOXP3
gene, a key regulator of immune tolerance, located in the
X-chromosome at Xp11.23-Xq13.3 [12-17]. It is critical
for the function of CD4+CD25+ regulatory T-cells (TREG)
and for the maintenance of peripheral immunologic toler-
ance [17,18].* Correspondence: daniele.zama@gmail.com
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We describe a 12-year-old boy born at term from natural
birth after an uncomplicated pregnancy from unrelated
parents, referred to our hospital for severe enteritis started
one month before with liquid mucus-haematic diarrhoea
(height: 50th centile, weight: 10th centile, regularly vacci-
nated). No potentially triggering events have been reported,
such as vaccinations, viral infections or changes in nutri-
tion. In his past history he had recurring episodes of mild
atopic dermatitis since the first year of life, a high level of
total IgE (400 UI/L), and a constipated bowel (once every
two/three days).
On admission, he was dehydrated (7% of weight loss).
Blood tests revealed hypoproteinaemia and hypogamma-
globulinemia (Table 1), so albumin was replaced.
Abdominal ultrasound highlighted wall thickening of
the bowel loops. Esophagogastroduodenoscopy (EGDS)
and colonoscopy revealed ulcerative lesions at the stomach,
duodenum, terminal ileum and colon, giving rise to a
suspect of inflammatory bowel disease. Biopsies revealed
villous blunting and inflammatory infiltration of the
mucosa. After starting intravenous methylprednisolone,
metronidazole and parenteral nutrition a partial remission
was observed.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 The molecular and clinical features of the patient with IPEX who received sirolimus have been reported
Patient Mutation Clinical features Histology Management Outcome Ref.
Age at onset
age at dg
Nucleotide
change
AA
change
FOXP3 Molecular defect Previous therapy SIR HSCT
1
7 y
10 y
c.968-
20A>C
NA NA NA Dermatitis, enteropathy
Lymphoplasmocellular
eosinophilic infiltrate.
Villous atrophy.
Steroids, AZA, CsA,
FK, MTX. TPN, Total
colectomy at 10 y
Y N
Stable at 16 yr
on SIR+MTX.
[19]
2*
2 m
NA
NA
Enteropathy,
erythematous
eczema-like
dermatitis
Lymphoplasmocellular
infiltrate with marked
eosinophilia. High rate
of enterocyte apoptosis.
Subtotal villous atrophy.
Steroids, FK, AZA Y N
Stable for 1.5 yr
on SIR+AZA
[19]
3*
2 m
NA
NA
Enteropathy,
erythematous
eczema-like
dermatitis
Similar findings with
that of his brother (pt.4)
Steroids, FK; AZA Y N
Stable for 6 m
on SIR+AZA
[19]
4
2 y
4 y
1061 delC
Frameshift
P354Q
NA
Premature stop
codon. Truncated
FKH domain
Enteropathy,
nonspecific
dermatitis
Mild villous blunting
Metronidazole,
steroids, mesalamine,
IFX, AZA, 6-MP
Y N Stable at 7 yr [20]
5
1 w
7 y
200G>T Q70H NA
Predicted abnormal
reading frame
Eczema,
enteropathy,
AHA, ITP, arthritis
Inflammation with
villous atrophy
IVIG, steroids, TPN,
antibiotics
Y N Stable at 8 yr [20,21]
6*
3 w
NA
g.-6247-
4859del
NA ↓
Accumulation of
unspliced mRNA
Skin/food
allergies, Enteropathy,
erythematous-
eczematous skin rash
Lymphoplasmocellular
infiltrate with marked
eosinophilia. High
rate of enterocytes
apoptosis. Severe to
total villous atrophy
Steroids, FK,
AZA TPN
Y N
Stable for 6 yr
on SIR+AZA
[22]
7*
2 m
NA
g.-6247-
4859del
NA ↓
Accumulation of
unspliced mRNA
Skin/food allergies,
Eczema, Enteropathy
NA
Steroids, FK,
AZA TPN
Y N
Stable for 4 yr
on SIR+AZA
[22]
8
5 w
NA
g.-6247-
4859del
NA ↓
Accumulation of
unspliced mRNA
Enteropathy,
Eczema, Allergy
NA Steroids, FK, AZA Y N
Stable at 9 yr
on SIR+AZA
[23]
9
3 w
NA
g.-6247-
4859del
NA ↓
Accumulation of
unspliced mRNA
Enteropathy,
Eczema, HP
gastritis, Allergy
NA Steroids, FK AZA Y N
Stable at 6 yr
on SIR+AZA
[23]
10
Birth
NA
g.-1121
T>G
F374C ↓
Full length FOXP3
with abnormal
FKH domain
T1DM, HTH,
Enteropathy,
Eczema, AHA, ITP,
Allergy.
NA Steroids, FK506 Y N
Died at 14 m
during HSCT
induction
[23]
11
6 w
NA
751-753
del GAG
E251del ↓
Disrupts FOXP3
oligomerisation
Enteropathy, Eczema,
HTH, Interstitial
Nephritis, AHA, Allergy.
NA FK506 Y Y
Died at 10 yr
after HSCT
[23]
12
1 m
6 y
1150G>A A384T ↓
Full length FOXP3
with abnormal
FKH domain
Enteropathy, Eczema,
FTT, T1DM, AHA,
Interstitial Pneumonia,
Alopecia, Thyroiditis.
Eosinophil infiltration
without villous atrophy
IVIG, CsA, steroids,
TPN, fludarabine-autologous
lymphocytes, FK, MTX,
Rituximab, cyclophosphamide.
Y N
Stable at 16 yr
on others
drugs
[4,24,25]
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Table 1 The molecular and clinical features of the patient with IPEX who received sirolimus have been reported (Continued)
13
Birth
7 w
1150G>A A384T ↓
Full length FOXP3 with
abnormal FKH domain
Enteropathy, T1DM,
Exfoliative Dermatitis,
HTH, Pancytopenia
NA TPN Y N Died at 7 w [26]
14
Birth
4½ y
AAUAAA/
AAUAAG
NA ↓
Polyadenylation defect
resulting in unstable
FOXP3 mRNA
Enteropathy, Dermatitis,
FTT, T1D.
NA MTX, steroids, TPN. Y Y Stable at 1 yr [27]
15 1 w 1015C>G P339A ↓
Missense mutation.
Predicted to yield full
length FOXP3
Enteropathy, Eczema,
T1DM, FTT, Euthyroid
Thyroiditis, AIH, AHA
Villous atrophy Steroids, FK; AZA Y N
Died at 5.5 m
before HSCT
[28]
16
3 m
1y
Exon 10 NA NA NA
FTT, Enteropathy,
Eczematous Dermatitis,
ITP stomatitis
NA
Cyclophosphamide,
VCR, TPN
Y N
Stable 2½ yr
on other drugs
[29]
*Brothers; 6-MP 6-Mercaptopurina; AHA autoimmune haemolytic anaemia; AIH Autoimmune hepatits; AZA Azathioprine; CsA Cyclosposporine; FTT: failure to thrive; FK: tacrolimus; HSCT hematopoietic stem cell
transplantation; HTH Hypothyroidism; IFX Infliximab; ITP immune thrombocytopenic purpura; IVIG Intravenous Immunoglobulin; Y: Yes; yr: years; m: months; MTX Methotrexate; NA Not Available; N: No; Ref. References;
SIR Sirolimus; T1DM Type 1 Diabetes mellitus; TPN Total Parenteral Nutrition; VCR Vincristine; w: weeks; ↓: reduction of expression.
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and colonoscopy were repeated, with a superimposable
picture. Particularly, the biopsies of the colon showed
lympho-granulocytic acute inflammation with Graft ver-
sus Host Disease-like aspect, a lesion typically reported
in IPEX (Figure 1) [30]. Due to the inability to control
the symptoms the patient underwent ileostomy.
Despite the age of the patient was atypical for the
onset of IPEX, we evaluated the presence of autoanti-
bodies to harmonin, which resulted positive (>100 U.A.).
Then, diagnosis was confirmed by the genetic examination
of FOXP3 gene, revealing a mutation in the exon 9
(1040G > A), with substitution of Arginine to Histidine
(R347H). The mother resulted negative. The total number
of lymphocyte and lymphocyte subpopulations was
normal, particularly TREG were 5% of the total number.
Intravenous cyclosporine (range: 200-350 mg/dl) and
methylprednisolone (2 mg/kg) were started, which reduced
diarrhea and abdominal pain. After sixty days of parenteral
nutrition the patient returned to oral feeding with the
normalization of albumin levels (Table 1). Because of
the onset of post-prandial hyperglycaemias, we excluded
T1DM (Table 1) and glycaemia normalized after tapering
steroid therapy. For a new worsening of the disease we
introduced sirolimus (0.15 mg/kg/day; range: 8-12 mg/dl).
The patient improved with a progressive reduction of
intensity and frequency of abdominal pain and mucus
emission. A new colonoscopy highlighted a marked
decrease of the inflammation. After thirty-four days since
the beginning of sirolimus, cyclosporine was suspended.
After twelve months the patient is well, without recur-
rence of the disease.A
C
Figure 1 Biopsy of the colon mucosa highlights a marked inflammato
prevalence of lymphocytes CD8+ (red; B) than lymphocytes CD4+ (red; C).Conclusions
This case indicates that IPEX can have an atypical age of
presentation. Thus, it should always be considered in the
differential diagnosis of intractable diarrhea.
Four patients have been previously reported with IPEX
with the same amino-acid substitution (R347H) found
in our patient. The age of onset for all these subjects
was within the first year of life and the first symptoms
were recurrent ear infection, high IgE levels, T1DM,
and gastritis. All had gastrointestinal symptoms with
failure to thrive: two intractable diarrhea, two severe
gastritis with mucosal atrophy or eosinophilic infiltra-
tion. Other symptoms were: coombs-negative haemolytic
anaemia, food allergy, pancreatic exocrine failure, intract-
able hypertension, intestinal metaplasia, steatorrhea, and
hypogammaglobulinemia. Patients received corticosteroid
and calcineurin inhibitors. One patient died after allogen-
eic hematopoietic stem cell transplantation (HSCT) due
to an infection.
Recently, evidence that patients with a severe form of
IPEX may have circulating FOXP3+ T cells, as it is the
case of our patient, which suggests that the cellular basis
for the disease may be a result of a functional defect of
Treg cells [1,26]. Mainly, R347H mutated-FOXP3 has
been demonstrated as effective as wild-type-FOXP3 in
converting normal T cell into Treg in vitro [31] and in
maintaining the ability to suppress the production of
cytokines, hallmark of Treg cells, conferring suppressive
capacity on CD4+ T cells.
In 2005, three patients were successfully treated with
sirolimus [19]. Since then, 16 patients received sirolimus
and nine are in complete or partial remission (Table 2).B
D
ry infiltrate. (A: H&E 5x) with a GVHD-like aspect characterized by a
Rare lymphocytes expressing FOXP3 were found (red; D).
Table 2 Variables of our patient at the time of admission to our hospital, when he started the second line therapy
with Sirolimus and after three months since the begging of this therapy
Variables Reference range, age and sex-adjusted Admission Start SIROLIMUS 3 months after SIROLIMUS
White-cell count — per mm3 4.5 - 13.5 15.01 4.04 5.01
Hemoglobin — g/dl 11.5 - 14.5 16.3 11.7 11.5
Hematocrit —% 35 - 42 46.0 34.4 35.7
Differential count —%
Neutrophils 40.0 - 74.0 89.6 51.2 48.0
Lymphocytes 19.0 - 48.0 6.6 30.3 38.0
Monocytes 3.0 - 9.0 2.4 13.5 7.6
Eosinophils 0.0 - 6.0 0.4 1.7 4.4
Basophils 0.0 - 1.5 0.3 1.1 0.7
Platelet count — per mm3 250 - 550 522 247 273
Glucose — mg/dl 60 - 100 125 107 77
Insulinemia — microU/mL 7 - 24 6.8
C-peptide — ng/mL 1.1 - 4.4 2.7
Islet cell autoantibodies Neg Neg Neg
Glutamic acid decarboxylase— UI/ml <10 Neg Neg Neg
>10 Pos
UREA — mg/dl 15 - 50 72 40 18
Creatinine — mg/dl 0.5 - 1 0.91 0.54 0.35
Uric Ac. — mg/dl 2.2 - 6.6 8.6 5.2 3.4
Total Colesterol — mg/dl 130 - 204 121
TG — mg/dl 31 - 108 40
HDL — mg/dl > 35 62
LDL — mg/dl < 170 50
Electrolytes — mmol/L
Sodium 136 - 146 128 139 142
Potassium 3.5 - 5.3 5.5 4.3 4.3
Chlorine 98 - 106 85 103 105
Calcium 8.8 - 10.8 9.6 9.3 9.2
Phosphorus — mg/dl 2.9 - 5.4 7.6 5 4.4
Magnesium — mg/dl 1.6 - 2.6 2.2 1.6 2.1
Plasma Osmolarity — mOsm/L 278 - 305 266
Protein — g/dl
Total 6,4 - 8.1 4.1 6.2 6.7
Albumin 3.5 - 5 2.4 4.2 4.3
γ –Globulin —% 11.1 - 18.8 10.5 11.4 13.4
Bilirubin — mg/dl
Total 0.20 - 1.10 1.54 0.44 0.3
Direct/Indirect 0.00-0.30/< 0.80 0.48/1.06 0.21/0.23 0.1/0.2
AST/ALT — U/L < 38/< 41 44/34 16/10 22/17
Total Amylase — U/L 30 - 100 50 60
Iron — μg/dl 53 - 119 47 52
U.I.B.C./T.I.B.C. — μg/dl 110-330/250-400 300/347 273/325
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Table 2 Variables of our patient at the time of admission to our hospital, when he started the second line therapy
with Sirolimus and after three months since the begging of this therapy (Continued)
Ferritin — ng/mL 7 - 140 22 16
TSH — microU/mL 0.6 - 6.3 1.93 1.02
FT3 — pg/mL 2.5 - 5.5 3.6 4.1
FT4 — pg/mL 9.0 - 17.0 20.7 12.9
ATA — UI/mL < 115 23 16
Anti TPO Ab — UI/mL < 34 12 13
ESR — mm < 15 6 15 9
CRP — mg/dl < 0.5 0.05 2.05 0.09
Ab anti harmonine IgG — U.A. < 3.0 absent
>100
> 0.3 present
ANA < 1:80 < 1:80
AMA < 1:40 < 1:40
ENA < 0,7 Neg Neg
0.7 - 1-0 Bl
> 1.0 Pos
ALT Alanine aminotransferase, AMA Anti-mitochondrial antibodies, ANA Antinuclear antibodies, anti-TPO Ab Anti-ThyroidPeroxidase Antibodies, AST aspartate
aminotransferase, ATA Anti-Thyroglobulin Antibodies, Bl Borderline, CRP C-reactive protein, ENA Extractable Nuclear Antigens, ESR erythrocyte sedimentation rate,
FT3 Free Triiodothyronine, FT4 Free Thyroxine, HDL High-Density Lipoprotein, LDL Low-Density Lipoprotein, Neg Negative, Pos Positive, T.I.B.C. Total iron-binding
capacity, TG triglycerides, TSH Thyroid-Stimulating Hormone, U.I.B.C. Unsaturated Iron Binding Capacity.
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the calcineurin inhibitors, with less toxic effects, it can
be considered as a valid therapeutic option for bringing
these patients to HSCT in their best clinical condition.
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